Wealth Enhancement Advisory Services LLC Has $105,000 Stake in Aldeyra Therapeutics, Inc. $ALDX

Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) by 150.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,286 shares of the biotechnology company’s stock after purchasing an additional 16,376 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Aldeyra Therapeutics were worth $105,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Inspirion Wealth Advisors LLC bought a new stake in shares of Aldeyra Therapeutics during the second quarter valued at approximately $38,000. Capital Advisors Wealth Management LLC bought a new position in shares of Aldeyra Therapeutics in the first quarter valued at approximately $62,000. Pallas Capital Advisors LLC bought a new position in shares of Aldeyra Therapeutics in the second quarter valued at approximately $68,000. CWM LLC increased its position in shares of Aldeyra Therapeutics by 1,164.4% during the first quarter. CWM LLC now owns 19,244 shares of the biotechnology company’s stock valued at $111,000 after acquiring an additional 17,722 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Aldeyra Therapeutics during the first quarter valued at approximately $132,000. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ALDX shares. Zacks Research raised Aldeyra Therapeutics to a “hold” rating in a research report on Friday, August 8th. Wall Street Zen raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 21st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Aldeyra Therapeutics in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Aldeyra Therapeutics currently has an average rating of “Hold” and a consensus target price of $9.50.

Insider Transactions at Aldeyra Therapeutics

In related news, insider Stephen Machatha sold 22,073 shares of the company’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $5.15, for a total value of $113,675.95. Following the transaction, the insider directly owned 221,799 shares of the company’s stock, valued at approximately $1,142,264.85. This represents a 9.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 8.50% of the company’s stock.

Aldeyra Therapeutics Stock Performance

ALDX stock opened at $5.39 on Monday. Aldeyra Therapeutics, Inc. has a fifty-two week low of $1.14 and a fifty-two week high of $7.20. The company has a market capitalization of $322.86 million, a price-to-earnings ratio of -6.34 and a beta of 0.83. The business’s 50 day moving average price is $5.42 and its two-hundred day moving average price is $4.00.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.05. Sell-side analysts forecast that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.